DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ℹ️ Observational Association Only Evidence
A nationwide Swedish cohort compared GLP-1 receptor agonists with SGLT2 inhibitors in patients with type 2 diabetes. The analysis found a higher relative risk of anterior ischemic optic neuropathy, but few events overall.
Clinical Considerations
- Event counts were small, with 62 cases among GLP-1 users and 64 among SGLT2 users.
- Five-year absolute risks remained low, at 0.12% for GLP-1 users and 0.07% for comparators.
- The association attenuated in metformin-restricted analyses, suggesting possible confounding by diabetes severity.
- Subgroup analyses by A1c, smoking, and individual GLP-1 agent had wide confidence intervals.
Practice Applications
- Interpret this as association, not established causality.
- Recognize low absolute risk despite elevated relative estimates.
- Monitor future neuro-ophthalmic safety data for GLP-1 agents.
- Avoid overgeneralizing findings to obesity patients without diabetes.
